From: Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer
Features | No. of patients | ALPK2 expression | P value | |
---|---|---|---|---|
Low | High | |||
All patients | 188 | 79 | 109 | |
Age (years) | 0.728 | |||
< 49 | 90 | 39 | 51 | |
≥ 49 | 98 | 40 | 58 | |
Grade | < 0.001 | |||
1 | 23 | 19 | 4 | |
2 | 33 | 28 | 5 | |
3 | 113 | 19 | 94 | |
Stage | 0.499 | |||
I | 144 | 56 | 88 | |
II | 14 | 7 | 7 | |
III | 12 | 6 | 6 | |
IV | 2 | 0 | 2 | |
T infiltrate | 0.450 | |||
T1 | 144 | 56 | 88 | |
T2 | 22 | 10 | 12 | |
T3 | 6 | 3 | 3 | |
Lymphatic metastasis (N) | 0.710 | |||
N0 | 161 | 64 | 97 | |
N1 | 11 | 5 | 6 |